The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 237 of the 241 references it cites were found in a registry or an index.
Abstract
Objective: To develop clinical practice guidelines for the management of patients with primary aldosteronism. Participants: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee of the Endocrine Society, six additional experts, a methodologist, and a medical writer. The guideline was cosponsored by American Heart Association, American Association of Endocrine Surgeons, European Society of Endocrinology, European Society of Hypertension, International Association of Endocrine Surgeons, International Society of Endocrinology, International Society of Hypertension, Japan Endocrine Society, and The Japanese Society of Hypertension. The Task Force received no corporate funding or remuneration. Evidence: We searched for systematic reviews and primary studies to formulate the key treatment and prevention recommendations. We used the Grading of Recommendations, Assessment, Development, and Evaluation group criteria to describe both the quality of evidence and the strength of recommendations. We used “recommend” for strong recommendations and “suggest” for weak recommendations. Consensus Process: We achieved consensus by collecting the best available evidence and conducting one group meeting, several conference calls, and multiple e-mail communications. With the help of a medical writer, the Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and Council successfully reviewed the drafts prepared by the Task Force. We placed the version approved by the Clinical Guidelines Subcommittee and Clinical Affairs Core Committee on the Endocrine Society's website for comments by members. At each stage of review, the Task Force received written comments and incorporated necessary changes. Conclusions: For high-risk groups of hypertensive patients and those with hypokalemia, we recommend case detection of primary aldosteronism by determining the aldosterone-renin ratio under standard conditions and recommend that a commonly used confirmatory test should confirm/exclude the condition. We recommend that all patients with primary aldosteronism undergo adrenal computed tomography as the initial study in subtype testing and to exclude adrenocortical carcinoma. We recommend that an experienced radiologist should establish/exclude unilateral primary aldosteronism using bilateral adrenal venous sampling, and if confirmed, this should optimally be treated by laparoscopic adrenalectomy. We recommend that patients with bilateral adrenal hyperplasia or those unsuitable for surgery should be treated primarily with a mineralocorticoid receptor antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Algorithm for the detection, confirmation, subtype testing, and treatment of PA. a We recommend unilateral laparoscopic adrenalectomy for patients with documented unilateral PA (ie, APA or UAH) (1 ⎪ QQQE ). If a patient is unable or unwilling to undergo surgery, we recommend medical treatment including a MR antagonist (1 ⎪ QQQE ). If an ARR-positive patient is unwilling or unable to undergo further investigations, we similarly recommend medical treatment including an MR antagonist (1 ⎪ QQEE ). b Instead of proceeding directly to subtype classification, we recommend that patients with a positive ARR undergo one or more confirmatory tests to definitively confirm or exclude the diagnosis (1 ⎪ QQEE ). However, in the setting of spontaneous hypokalemia, undetectable renin, and PAC > 20 ng/dL (550 pmol/L), we suggest that there may be no need for further confirmatory testing (2 ⎪ QEEE ). c We recommend that when surgical treatment is feasible and desired by the patient, an experienced radiologist should use AVS to make the distinction between unilateral and bilateral adrenal disease (1 ⎪ QQQE ). Younger patients ( < age 35) with spontaneous hypokalemia, marked aldosterone excess, and unilateral adrenal lesions with radiological features consistent with a cortical adenoma on adrenal CT scan may not need AVS before proceeding to unilateral adrenalectomy (2 ⎪ QEEE ). [Adapted from J. W. Funder et al: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab . 2008;93:3266-3281 (3), with permission. © Endocrine Society.]](https://figures.cochat.ai/paper-figures/aaade82f5c4b425bbdee69e74321806d/the-management-of-primary-aldosteronism-case-detection-diagnosis-and-treatment-figure-1.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common types of secondary hypertension in adults are renal parenchymal disease, renovascular hypertension, primary aldosteronism, chronic sleep apnea, and substance/drug-induced.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A specific cause of secondary hypertension can be identified in 5%-10% of hypertensive patients (Table 11).”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypokalemia, which reduces aldosterone secretion, should be corrected with oral K+ supplements before testing.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with unilateral disease (50%; aldosterone-producing adenoma or, much less frequently, unilateral hyperplasia) respond to unilateral laparoscopic adrenalectomy with complete cure (≈50%) or improvement (≈50%) in BP control.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group, an international group with expertise in the development and implementation of evidence-based guidelines (2).”
MethodNational High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) · PEDIATRICS · doi:10.1542/peds.114.2.s2.555 · Cited by 6,938
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
Funder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554 · cited 3×
“The recommendations and suggestions made by the Task Force were subject to extensive consultation before being published in the Journal of Clinical Endocrinology and Metabolism in 2008 (3).”
MethodSelf-citationEvidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547 · cited 2×
“Several outcome studies also have provided evidence that PA patients are particularly at risk of cardiovascular/ renal complications, including arrhythmias, myocardial infarction, strokes, chronic kidney disease, and death, compared with age-, sex-, and BP-matched essential hypertensives (30, 33, 156).”
BackgroundResultA prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467 · cited 2×
“However, some groups have suggested that when clinicians administer a bolus injection of cosyntropin and sample the adrenal veins simultaneously, cosyntropin does not improve the diagnostic accuracy of AVS, and, in fact, cosyntropin may increase secretion from the nonadenomatous gland to a greater degree than from the…”
BackgroundSelf-citation
Research works printed but not linked: 3
- 15. Tucker RM, Labarthe DR. Frequency of surgical treatment for hypertensioninadultsattheMayoClinicfrom1973through1975. Mayo Clin Proc . 1977;52:549-545.
- 133. FardellaCE,PintoM,MossoL,Gómez-SánchezC,JalilJ,Montero J. Genetic study of patients with dexamethasone-suppressible aldosteronismwithoutthechimericCYP11B1/CYP11B2gene. J Clin Endocrinol Metab . 2001;86:4805-4807.
- 169. Jacobsen NE, Campbell JB, Hobart MG. Laparoscopic versus openadrenalectomyforsurgicaladrenaldisease. CanJUrol . 2003; 10:1995-1999.
Cited by
Items 501–600 of 1,002
RNA Sequencing Provides Novel Insights into the Transcriptome of Aldosterone Producing Adenomas
Backman, S., Åkerström, T., Maharjan, R., Cupisti, K., Willenberg, H. S., Hellman, P., & Björklund, P. (2019) · Scientific Reports · doi:10.1038/s41598-019-41525-2 · Cited by 27
Yin, Y., Ma, C., Yu, S., Liu, W., Wang, D., You, T., Cheng, Q., & Qiu, L. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0706 · Cited by 27
“The Endocrine Society Clinical Practice Guidelines [11] recommend several confirmatory tests for PA, including the quantification of serum aldosterone (sALD) or urinary aldosterone (uALD), in five steps to exclude or confirm the presence of and determine the subtype of PA.”
MethodUnilateral primary aldosteronism as an independent risk factor for vertebral fracture
Yokomoto‐Umakoshi, M., Sakamoto, R., Umakoshi, H., Matsuda, Y., Nagata, H., Fukumoto, T., Ogata, M., Ogawa, Y., & the Q‐AND‐A study group (2020) · Clinical Endocrinology · doi:10.1111/cen.14145 · Cited by 29
Endocrine causes of hypertension in pregnancy
Affinati, A. H., & Auchus, R. J. (2020) · Gland Surgery · doi:10.21037/gs.2019.12.04 · Cited by 28
“In the non-pregnant population, the next step in diagnosis is confirmatory testing (such as salt loading) and adrenal vein sampling (AVS) and/or imaging for subtype differentiation (20).”
BackgroundPrimary Aldosteronism and Pregnancy
Zelinka, T., Petrák, O., Rosa, J., Holaj, R., Štrauch, B., & Widimsky, J., Jr. (2020) · Kidney & Blood Pressure Research · doi:10.1159/000506287 · Cited by 28
Gurgenci, T., Geraghty, S., Wolley, M. J., & Yang, J. (2020) · Australian Journal of General Practice · doi:10.31128/ajgp-07-19-4995 · Cited by 26
Billmann, F. G., Billeter, A. T., Thomusch, O., Keck, T., Shishtawi, S. E., Langan, E. A., Strobel, O., & Müller-Stich, B. P. (2020) · Surgery · doi:10.1016/j.surg.2020.09.005 · Cited by 28
Bouhanick, B., Delchier, M. C., Lagarde, S., Boulestreau, R., Conil, C., Gosse, P., Rousseau, H., Lepage, B., Olivier, P., Papadopoulos, P., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002708 · Cited by 26
“As recommended, a minimum renin value of 5mIU/l was used to calculate the ARR [26].”
BackgroundInfluentialInoue, K., Kitamoto, T., Tsurutani, Y., Saito, J., Omura, M., & Nishikawa, T. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645488 · Cited by 28
DePietro, D. M., Fraker, D. L., Wachtel, H., Cohen, D. L., & Trerotola, S. O. (2021) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2020.12.029 · Cited by 26
Pecori, A., Buffolo, F., Burrello, J., Mengozzi, G., Rumbolo, F., Avataneo, V., D’Avolio, A., Rabbia, F., Bertello, C., Veglio, F., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab290 · Cited by 26
Saiki, A., Otsuki, M., Tamada, D., Kitamura, T., Mukai, K., Yamamoto, K. I., & Shimomura, I. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab174 · Cited by 30
“In an Endocrine Society Clinical Practice Guideline [2], the therapeutic target of MRA treatment is a relatively higher normalizing serum potassium concentration and a decrease in BP to eliminate the vascular, cardiac, and renal effects of aldosterone excess.”
BackgroundInfluentialChoy, K. W., Fuller, P. J., Russell, G. M., Li, Q., Leenaerts, M., & Yang, J. (2022) · BMJ · doi:10.1136/bmj-2021-065250 · Cited by 29
What We Know about and What Is New in Primary Aldosteronism
Ekman, N., Grossman, A. B., & Dworakowska, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020900 · Cited by 27
“According to current guidelines, AVS should be offered to all patients with a confirmed diagnosis of PA who can and wish to undergo surgical treatment [4,49].”
BackgroundInfluentialEffect of Moxonidine on the Aldosterone/Renin Ratio in Healthy Male Volunteers
Ahmed, A. H., Gordon, R. D., Ward, G., Wolley, M. J., McWhinney, B. C., Ungerer, J. P. J., & Stowasser, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3821 · Cited by 26
Self-citationTargeted treatment of primary aldosteronism – The consensus of Taiwan Society of Aldosteronism
Huang, K., Yu, C., Hu, Y., Chang, C., Chan, C., Liao, S., Tsai, Y., Chueh, S., Wu, V., Lin, Y., et al. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.01.006 · Cited by 26
Moraes, A. B., Cavalari, E. M. R., de Paula, M. P., Arruda, M., Curi, D., Leitão, R., de Mendonça, L. M. C., Farias, M. L. F., Madeira, M., & Neto, L. V. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0985-y · Cited by 28
Liang, K., Jahangiri, Y., Tsao, T., Tyan, Y., & Huang, H. (2019) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2019.04.039 · Cited by 26
Role of Aldosterone and Potassium Levels in Sparing Confirmatory Tests in Primary Aldosteronism
Umakoshi, H., Sakamoto, R., Matsuda, Y., Yokomoto‐Umakoshi, M., Nagata, H., Fukumoto, T., Ogata, M., & Ogawa, Y. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz148 · Cited by 28
Itcho, K., Oki, K., Gómez-Sánchez, C. E., Gómez-Sánchez, E. P., Ohno, H., Kobuke, K., Nagano, G., Yoshii, Y., Baba, R., Hattori, N., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.14062 · Cited by 26
“There are 2 main subtypes of PA: aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism.(3) In APA, CYP11B2 (aldosterone synthase) transcription is activated by intracellular Ca signaling, resulting in autonomous overproduction of aldosterone.”
BackgroundChoudhary, M. K., Värri, E. K. H., Matikainen, N., Koskela, J., Tikkakoski, A., Kähönen, M. A. P., Niemelä, O. J., Mustonen, J. T., Nevalainen, P. I., & Pörsti, I. H. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13115 · Cited by 30
Radiology report language positively influences adrenal incidentaloma guideline adherence
Watari, J., Vekaria, S., Lin, Y., Patel, M., Kim, H., Kang, F., Lubitz, S. E., Beninato, T., & Laird, A. M. (2021) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2021.06.015 · Cited by 27
Rossi, G. P., & Funder, J. W. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09295 · Cited by 28
Self-citationAsbach, E., Bekeran, M., König, A., Lang, K., Hanslik, G., Treitl, M., Ladurner, R., Bidlingmaier, M., Beuschlein, F., Quinkler, M., et al. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1027-6472 · Cited by 25
“27 of the 55 IAH patients had a follow-up investigation 12 months after initiation of mineralocorticoid receptor antagonist therapy.”
BackgroundMethodSelf-citationRosário, P. W., & Calsolari, M. R. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0859-1020 · Cited by 25
“The following subjects were excluded from the group of normocalcemic patients: patients using diuretics, lithium, bisphosphonates, denosuamb, recombinant PTH, and corticosteroids; patients with primary aldosteronism (investigated in the recommended situations [17]), a suspicion or known diagnosis of malabsorption synd…”
BackgroundQuality of life in primary aldosteronism: A prospective observational study
Buffolo, F., Cavaglià, G., Burrello, J., Amongero, M., Tetti, M., Pecori, A., Sconfienza, E., Veglio, F., Mulatero, P., & Monticone, S. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13419 · Cited by 25
Wurth, R., Tirosh, A., Kamilaris, C. D. C., Camacho, J., Faucz, F. R., Maria, A. G., Berthon, A. S., Papadakis, G. Z., Nilubol, N., Hamimi, A., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa162 · Cited by 26
“A stepwise case confirmation and subtype classification for primary aldosteronism (PA) was performed in all included patients [23].”
MethodSelf-citationHow common is primary aldosteronism?
Hundemer, G. L., Kline, G. A., & Leung, A. A. C. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000702 · Cited by 26
“In keeping with the concept of primary aldosteronism as a discrete (and largely surgical) entity, hypertension and endocrine guidelines developed ARR screening recommendations based largely upon expert consensus with acknowledgment that in the absence of high-quality prospective clinical trials of mineralocorticoid re…”
BackgroundInfluentialAldosterone-Regulating Receptors and Aldosterone-Driver Somatic Mutations
Lim, J. S., Plaska, S. W., Rege, J., Rainey, W. E., & Turcu, A. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.644382 · Cited by 28
Burrello, J., Tetti, M., Forestiero, V., Biemmi, V., Bolis, S., Pomatto, M. A. C., Amongero, M., Silvestre, D. D., Mauri, P., Vassalli, G., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17136 · Cited by 25
Marazzato, J., Blasi, F., Golino, M., Verdecchia, P., Angeli, F., & Ponti, R. D. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9040110 · Cited by 31
“5% in hypertensive patients to 17–23% in those with resistant HTN [92].”
BackgroundRole and Regulation of MicroRNAs in Aldosterone-Mediated Cardiac Injury and Dysfunction in Male Rats
Ball, J. P., Syed, M., Maranon, R. O., Hall, M. E., Roshan, K. C., Reckelhoff, J. F., Cardozo, L. L. Y., & Romero, D. G. (2017) · Endocrinology · doi:10.1210/en.2016-1707 · Cited by 25
“according to the latest clinical guidelines for the management of primary aldosteronism (77) [Supplemental”
MethodAdrenal venous sampling for primary aldosteronism: laboratory medicine best practice
Kline, G. A., & Holmes, D. T. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204423 · Cited by 26
“4 Note, however, that clinicians may elect to refer younger patients ( 35 years) with clinical features more suggestive of APA (overt hypokalaemia and low-density unilateral adrenal adenoma on CT) directly to surgery without AVS.”
BackgroundStowasser, M., Ahmed, A. H., Guo, Z., Wolley, M. J., Ungerer, J. P. J., McWhinney, B. C., Poglitsch, M., & Gordon, R. D. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-121468 · Cited by 25
“In recent decades, the gradual acceptance of PA as a common, specifically treatable and potentially curable cause of hypertension has led to a marked intensification in efforts to enhance detection and diagnosis of the condition, culminating in the development and wide dissemination of international guidelines [10].”
BackgroundSelf-citationIncreased Urinary Extracellular Vesicle Sodium Transporters in Cushing’s Syndrome with Hypertension
Salih, M., Bovée, D. M., van der Lubbe, N., Danser, A. H. J., Zietse, R., Feelders, R. A., & Hoorn, E. J. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00065 · Cited by 33
“Plasma renin and aldosterone were measured midmorning after the patient had been up for at least 2 hours, with blood collection after the patient had been seated for 5 to 15 minutes (27).”
Violari, E. G., Arici, M., Singh, C., Caetano, C. M., Georgiades, C. S., Grady, J. J., Tendler, B. R., Shichman, S. J., & Malchoff, C. D. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.66 · Cited by 25
Pan, C., Liao, C., Tsai, C., Chen, Z., Chen, L., Hung, C., Liu, Y., Lin, P., Chang, C., Chang, Y., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013699 · Cited by 25
“5% in all patients with hypertension, 13% of patients with stage 3 hypertension, and 17% to 23% of patients with resistant hypertension.(1) Higher rates of long-term mortality and comorbidity have been reported in patients with PA”
BackgroundMethodThiesmeyer, J. W., Ullmann, T. M., Stamatiou, A. T., Limberg, J. N., Stefanova, D. I., Beninato, T. M., Finnerty, B. M., Vignaud, T., Leclerc, J., Fahey, T. J., et al. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2020.5011 · Cited by 25
Yang, J., Bell, D. A., Carroll, R. W., Chiang, C. Y., Cowley, D., Croker, E. E., Doery, J. C. G., Elston, M. S., Glendenning, P., Hetherington, J., et al. (2024) · Clinical Endocrinology · doi:10.1111/cen.15139 · Cited by 24
Self-citationPrimary Aldosteronism: The Next Five Years
Funder, J. W. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-119802 · Cited by 25
“What this demands at first blush is a return to the past, to the days of Helber et al. previously cited, and to screen patients with a higher probability of primary aldoster-onism (in the 2016 Guidelines [25], ~50 % of hypertensives) by a more representative aldosterone concentration.”
BackgroundSelf-citationAdrenal-sparing surgery: current concepts on a theme from the past
Perysinakis, I., Aggeli, C., Kaltsas, G., & Zografos, G. N. (2020) · HORMONES · doi:10.1007/s42000-020-00202-0 · Cited by 26
“Patients with primary aldosteronism, in whom lateralization of the disease has been documented preoperatively, have been traditionally treated with total unilateral adrenalectomy [28].”
BackgroundCardiomyopathies and Adrenal Diseases
Petramala, L., Concistrè, A., Olmati, F., Saracino, V., Chimenti, C., Frustaci, A., Russo, M. A., & Letizia, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145047 · Cited by 24
“The recommended treatment for PA is unilateral laparoscopic adrenalectomy in patients with proven unilateral PA, or medical treatment with mineralocorticoid receptor blockades in patients not eligible for surgery or with bilateral adrenal hyperplasia [4].”
BackgroundXu, F., Gao, Z., Wang, G., Gao, Y., Guo, Y. S., Guo, Y., & Zhou, Z. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.10.007 · Cited by 26
Update on Genetics of Primary Aldosteronism
Itcho, K., Oki, K., Ohno, H., & Yoneda, M. (2021) · Biomedicines · doi:10.3390/biomedicines9040409 · Cited by 25
“Primary aldosteronism (PA), which is a disorder of excess aldosterone secretion, is the most common form of secondary hypertension, with a prevalence of 5–10% among patients with hypertension [1].”
BackgroundScreening for primary aldosteronism is underutilised in patients with chronic kidney disease
Chauhan, K., Schachna, E., Libianto, R., Ryan, J., Hutton, H., Fuller, P. J., Wilson, S., Kerr, P. G., & Yang, J. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01267-3 · Cited by 24
“The Endocrine Society recommends that all medications that interfere with the ARR be withdrawn, in particular, mineralocorticoid receptor antagonists and other diuretics should be ceased at least 4 weeks before ARR testing [24].”
BackgroundHistopathology and Genetic Causes of Primary Aldosteronism in Young Adults
Nanba, K., Baker, J. E., Blinder, A., Bick, N. R., Liu, C., Lim, J. S., Wachtel, H., Cohen, D. L., Williams, T. A., Reincke, M., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac408 · Cited by 25
Self-citationChen, Z., Pan, C., Liao, C., Tsai, C., Chang, Y., Chang, C., Lee, B., Chiu, Y., Huang, W., Wang, S., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac649 · Cited by 24
Mulatero, P., Groessl, M., Vogt, B., Schumacher, C., Steele, R. E., Brooks, A., Hossack, S., & Brunner, H. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15713 · Cited by 26
“Aldosterone, produced by the adrenal gland, regulates fluid homeostasis by stimulating sodium reabsorption in exchange for potassium in the distal tubules and collecting duct of the kidney.(2,3) Inappropriately elevated aldosterone levels in the setting of high sodium status have been associated with hypertension and…”
BackgroundComparing ARR Versus Suppressed PRA as Screening Tests for Primary Aldosteronism
Marcelli, M., Bi, C., Funder, J. W., & McPhaul, M. J. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.22884 · Cited by 25
Self-citationSteroidomics-Based Screening for Primary Aldosteronism: Impact of antihypertensive Drugs
Constantinescu, G. A., Gruber, S., Fuld, S., Peitzsch, M., Schulze, M., Remde, H., Kürzinger, L., Yang, J., Yen, T., Williams, T. A., et al. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.23029 · Cited by 25
“16,17 18–20 With machine learning (ML), we have developed models to interrogate mass spectrometry-based steroid profiles and derive steroid-probability scores to both predict and subtype PA. 21,22 The above approach to predict and subtype PA using ML-derived steroid-probability scores has been evaluated under the PROS…”
InfluentialSelf-citationAdrenal incidentalomas: A guide to assessment, treatment and follow-up
Paschou, S. Α., Vryonidou, A., & Goulis, D. G. (2016) · Maturitas · doi:10.1016/j.maturitas.2016.07.017 · Cited by 28
Núñez, J., Goring, A., Javaheri, B., Razi, H., Gómez‐Nicola, D., Hesse, E., Pitsillides, A. A., Thurner, P. J., Schneider, P., & Clarkin, C. (2018) · European Cells and Materials · doi:10.22203/ecm.v035a20 · Cited by 25
Unique approaches to hypertension control in China
Wang, J. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.07.27 · Cited by 24
“There is guideline and consensus on the diagnosis and treatment of primary aldosteronism (21,22).”
BackgroundAntifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess
Beck, K. R., & Odermatt, A. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111168 · Cited by 28
Surgical Outcomes of Aldosterone-Producing Adenoma on the Basis of the Histopathological Findings
Wang, H., Wang, F., Zhang, Y., Wen, J., Dong, D., Chang, X., Sun, H., Ma, X., Cui, Y., Chen, S., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.663096 · Cited by 24
Primary aldosteronism and pregnancy
Medved, V. І., Kyrylchuk, M. Y., & Husieva, A. Y. (2022) · Reproductive Endocrinology · doi:10.18370/2309-4117.2022.63.39-46 · Cited by 24
Spinal instability resulting from bilateral mini-hemilaminectomy and pediculectomy
Arthurs, G. (2009) · Veterinary and Comparative Orthopaedics and Traumatology · doi:10.3415/vcot-08-09-0092 · Cited by 27
Deng, L., Xiong, Z., Li, H., Lei, X., & Cheng, L. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.04.016 · Cited by 24
The Time has Come for Systematic Screening for Primary Aldosteronism in All Hypertensives ∗
Maiolino, G., Calò, L. A., & Rossi, G. P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.041 · Cited by 25
Primary aldosteronism in patients with adrenal incidentaloma: is screening appropriate for everyone?
Stavropoulos, K., Imprialos, K. P., Katsiki, N., Petidis, K., Kamparoudis, A., Petras, P., Georgopoulou, V., Finitsis, S., Papadopoulos, C., Athyros, V. G., et al. (2018) · The Journal of Clinical Hypertension · doi:10.1111/jch.13291 · Cited by 23
Demirkıran, A., Everaars, H., Elitok, A., van de Ven, P. M., Smulders, Y. M., Dreijerink, K. M. A., Tanakol, R., & Özcan, M. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13585 · Cited by 23
The effect of medication on the aldosterone‐to‐renin ratio. A critical review of the literature
Alnazer, R. M., Veldhuizen, G. P., Kroon, A. A., & de Leeuw, P. W. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14173 · Cited by 26
Prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea
Yoon, M., Hong, N., Ha, J., Lee, C. J., Ku, C. R., Rhee, Y., & Park, S. (2022) · Hypertension Research · doi:10.1038/s41440-022-00948-7 · Cited by 24
“In patients with a positive screening result, a saline infusion test (SIT) was performed to confirm the diagnosis of PA [1, 11, 19].”
BackgroundMethodInfluentialManagement and Outcomes of Primary Aldosteronism in Pregnancy: A Systematic Review
Sanga, V., Rossitto, G., Seccia, T. M., & Rossi, G. P. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.18858 · Cited by 26
Primary aldosteronism and obstructive sleep apnea: What do we know thus far?
Loh, H. H., & Sukor, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.976979 · Cited by 24
Liquid chromatography-tandem mass spectrometry in clinical laboratory protein measurement
Ma, Y., Wang, D., Li, H., Ma, X., Zou, Y., Mu, D., Yu, S., Cheng, X., & Qiu, L. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119846 · Cited by 25
Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Владимировна, А. А., Alekseeva, T. A., Ambatiello, L. G., Balanova, Y. А., Bragina, A. E., Danilov, N. M., Drapkina, O. M., et al. (2024) · Systemic Hypertension · doi:10.38109/2075-082x-2024-4-5-109 · Cited by 28
Cesari, M., Ceolotto, G., Rossitto, G., Maiolino, G., Seccia, T. M., & Rossi, G. P. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-017-0192-5 · Cited by 23
Kline, G. A., Leung, A. A. C., So, B., Chin, A., Harvey, A. M., & Pasieka, J. L. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001693 · Cited by 24
Expression of aldosterone synthase CYP11B2 was inversely correlated with longevity
Hayashi, T., Zhang, Z., Al‐Eyd, G., Sasaki, A., Yasuda, M., Oyama, M., Gómez-Sánchez, C. E., Asakura, H., Seki, T., Mukai, K., et al. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.04.010 · Cited by 23
“Subtypes of primary aldosteronism Primary aldosteronism (PA) is the most common cause of secondary hypertension [1,2].”
BackgroundDiverse Responses of Autoantibodies to the Angiotensin II Type 1 Receptor in Primary Aldosteronism
Williams, T. A., Jaquin, D., Burrello, J., Philippe, A., Yang, Y., Rank, P., Nirschl, N., Sturm, L., Hübener, C., Dragun, D., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13156 · Cited by 23
Self-citationAdolf, C., Heinrich, D. A., Holler, F., Lechner, B., Nirschl, N., Sturm, L., Görge, V., Riester, A., Williams, T. A., Treitl, M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz051 · Cited by 26
“The main difference to their study protocol was the higher starting dosage of 50 to 100 mg/d for MRA treatment compared with low-dose treatment with a starting dose of 25 to 50 mg/d, in accordance with Endocrine Society Practice Guidelines (10), in the current study.”
BackgroundMethodSelf-citationSpecial Article - The management of resistant hypertension: A 2020 update
Carey, R. M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.08.001 · Cited by 28
Self-citationHigh Prevalence of Autonomous Aldosterone Production in Hypertension: How to Identify and Treat It
Wannachalee, T., Lieberman, L., & Turcu, A. F. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01176-7 · Cited by 24
Castro, M. A., Paja, M., Boillos, M. G., Peris, B. P., Corrales, E. P., Cano, A. M. G., Ramírez, P. A. P., Rojas‐Marcos, P. M., Ruiz-Sánchez, J. G., Delgado, A. V., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003284 · Cited by 23
“The treatment of choice for bilateral adrenal hyperplasia is medical treatment with mineralocorticoid receptor antagonist (MRA) and in unilateral PA, the ideal treatment is unilateral adrenalectomy [3].”
BackgroundMethodHolmqvist, L. D., Boström, K. B., Kahan, T., Schiöler, L., Hasselström, J., Hjerpe, P., Wettermark, B., & Manhem, K. (2016) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2016.08.008 · Cited by 28
Update on Low-Renin Hypertension: Current Understanding and Future Direction
Shah, S. S., Fuller, P. J., Young, M. J., & Yang, J. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.23385 · Cited by 23
Marzano, L. A., Zoccatelli, F., Pizzolo, F., & Friso, S. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25104 · Cited by 22
Of channels and pumps: different ways to boost the aldosterone?
Bandulik, S. (2016) · Acta Physiologica · doi:10.1111/apha.12832 · Cited by 22
“For a detailed description of the complete workflow for the detection, confirmation, subtype testing and treatment of PA in patients, the reader is referred to the guideline of the endocrine society (Funder et al. 2016) and to reviews focusing on the clinical aspects of PA (Stowasser & Gordon 2016).”
MethodGkaliagkousi, Ε., Anyfanti, P., Triantafyllou, Α., Gavriilaki, E., Nikolaidou, B., Lazaridis, A. A., Vamvakis, A., & Δούμα, Σ. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.12.001 · Cited by 22
Yin, Y., Yu, S., Qiu, L., Wang, X., Wang, D., Ma, C., Zhang, K., & You, T. (2019) · Journal of Chromatography B · doi:10.1016/j.jchromb.2019.03.012 · Cited by 22
Rege, J., Turcu, A. F., & Rainey, W. E. (2020) · Gland Surgery · doi:10.21037/gs.2019.10.22 · Cited by 23
“Adrenal vein sampling (AVS) is the most reliable method for distinguishing between APA and BHA (10).”
BackgroundMethodInfluentialCastro, M. A., Guevara, M. I., Gutiérrez, M. C., Ramírez, P. A. P., Gimeno, P. G., Hanzu, F. A., & Lamas, C. (2020) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2020.08.010 · Cited by 27
“Pheochromocytoma, CS, PHA and adrenal carcinoma: based on the criteria established by the latest clinical practice guides.(2,31,36,38) Bilateral adenomas: adrenal lesions with features of adenoma and measuring over 1 cm in size in both adrenal glands.”
BackgroundMethodInfluentialTan, Y. K., Kwan, Y. H., Teo, D. C. L., Velema, M. S., Deinum, J., Tan, P. T., Zhang, M., Khoo, J. J. C., Loh, W. J., Gani, L. U., et al. (2021) · Endocrine Connections · doi:10.1530/ec-21-0125 · Cited by 22
Metabolic Subtyping of Adrenal Tumors: Prospective Multi-Center Cohort Study in Korea
Ku, E. J., Lee, C., Shim, J., Lee, S., Kim, K., Kim, S. W., Rhee, Y., Kim, H., Lim, J. S., Chung, C. H., et al. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1149 · Cited by 22
“NFA, CS, and PA were diagnosed according to current guidelines [5,17].”
BackgroundBaz, A. H. C., van de Wiel, E. C. J., Groenewoud, H., Arntz, M. J., Gotthardt, M., Deinum, J., & Langenhuijsen, J. F. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060779 · Cited by 22
Secondary hypertension as a cause of treatment resistance
Sudano, I., Suter, P. M., & Beuschlein, F. (2023) · Blood Pressure · doi:10.1080/08037051.2023.2224898 · Cited by 27
“To date, the definitive diagnosis of primary aldosteronism is a multistep procedure requiring expert knowledge (Figure 1) [18,19].”
BackgroundWoode, M. E., Wong, K., Reid, C. M., Stowasser, M., Russell, G. M., Gwini, S. M., Young, M. J., Fuller, P. J., Yang, J., & Chen, G. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003513 · Cited by 23
“At present, the Endocrine Society Guidelines recommend screening for primary aldosteronism in high-risk patients with characteristics such as a marked elevation in BP more than 150/100mmHg or resistant hypertension [11].”
BackgroundMethodInfluentialSelf-citationGrasso, M., Boscaro, M., Scaroni, C. M., & Ceccato, F. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0288-6 · Cited by 25
Familial hyperaldosteronism type III a novel case and review of literature
Fernández, N. P., Moreno, F., Morata, J., Gutiérrez, A. M., León, S., Mingo, C. D., Zúñiga, Á., & Calvo, F. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9481-0 · Cited by 22
Vecchiola, A., Fuentes, C., Barros, E., Martínez‐Aguayo, A., García, H., Allende, F. A., Solari, S., Olmos, R. I., Carvajal, C. A., Tapia-Castillo, A., et al. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz023 · Cited by 23
The relevance of cortisol co-secretion from aldosterone-producing adenomas
Bhatt, P. S., Sam, A. H., Meeran, K. M., & Salem, V. (2019) · HORMONES · doi:10.1007/s42000-019-00114-8 · Cited by 26
Outcomes After Surgery for Unilateral Dominant Primary Aldosteronism in Sweden
Sellgren, F., Koman, A., Nordenström, E., Hellman, P., Hennings, J., & Muth, A. (2019) · World Journal of Surgery · doi:10.1007/s00268-019-05265-8 · Cited by 24
Licorice induced pseudohyperaldosteronism, severe hypertension, and long QT
Smedegaard, S. B., & Svart, M. V. (2019) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-19-0109 · Cited by 25
The Demystification of Secondary Hypertension: Diagnostic Strategies and Treatment Algorithms
Hirsch, J. S., & Hong, S. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0790-8 · Cited by 26
Primary Aldosteronism in the Elderly
Mulatero, P., Burrello, J., Williams, T. A., & Monticone, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa206 · Cited by 23
Tezuka, Y., & Turcu, A. F. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0277 · Cited by 23
“Conversely, ACEIs, ARBs, and diuretics commonly lead to renin elevations (8,9,36).”
BackgroundInfluentialWannachalee, T., Caoili, E. M., Nanba, K., Nanba, A. T., Rainey, W. E., Shields, J. J., & Turcu, A. F. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa482 · Cited by 24
Resistant Hypertension: Where are We Now and Where Do We Go from Here?
Pathan, M. K., & Cohen, D. L. (2020) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s223334 · Cited by 24
“Untreated PA is associated with adverse cardiovascular effects, insulin resistance, and chronic kidney disease.(22) Cardiovascular effects are particularly notable: when compared with matched controls with essential hypertension, where PA patients were shown to have an increased risk of myocardial infarction (OR 6.”
BackgroundPhosphodiesterase 2A and 3B variants are associated with primary aldosteronism
Rassi-Cruz, M., Maria, A. G., Faucz, F. R., London, E., Vilela, L. A. P., de Santana, L. S., Benedetti, A. F. F., Goldbaum, T. S., Tanno, F. Y., Srougi, V., et al. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0384 · Cited by 24
Metadata
- Authors
- Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F.
- Affiliations
- Hudson Institute of Medical Research (AU)
- University of Virginia Health System (US)
- University of Padua (IT)
- Mayo Clinic (US)
- Klinikum of the Ludwig-Maximilians-University of Munich (M.R.), 80366 München, Bavaria, Germany
- Oita University (JP)
- The University of Queensland (AU)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-05-01
- Volume
- 101
- Issue
- 5
- Pages
- 1889-1916
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2290633895
- Semantic Scholar
- 36716f26ebd3b8e468f352d9132208c41e5688c0
- Cited by
- 2,925
- References
- 241
- Citations by year
- 2026: 236 · 2025: 397 · 2024: 315 · 2023: 329 · 2022: 329 · 2021: 315 · 2020: 293 · 2019: 238 · 2018: 200 · 2017: 188 · 2016: 72
- FWCI
- 233.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, case finding, aldosterone-renin ratio, adrenal computed tomography, adrenal vein sampling, laparoscopic adrenalectomy, bilateral adrenal hyperplasia, mineralocorticoid receptor antagonists, hypertension, hypokalemia
- MeSH terms
- Adrenal Glands, Adrenalectomy, Aldosterone, Mineralocorticoid Receptor Antagonists, Humans, Hyperaldosteronism, Renin, Evidence-Based Medicine, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.